These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 22520084

  • 21. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A.
    Thorax; 2012 Jan; 67(1):35-41. PubMed ID: 21828231
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 23. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial.
    Bateman ED, Bleecker ER, Lötvall J, Woodcock A, Forth R, Medley H, Davis AM, Jacques L, Haumann B, Busse WW.
    Respir Med; 2012 May; 106(5):642-50. PubMed ID: 22342538
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial.
    Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin JM.
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
    Lin J, Tang H, Chen P, Wang H, Kim MK, Crawford J, Jacques L, Stone S.
    Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
    [Abstract] [Full Text] [Related]

  • 26. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD.
    Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G.
    Respir Med; 2012 Jul; 106(7):970-9. PubMed ID: 22498110
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in persistent asthma: Phase 3 OD-INHALE Study.
    Kumar A, Jain MK, Barge VB, Kumar RS, Gupta N, Yadav H, Pal A, Redkar VE, Mondal A, Rathore RK, Daultani P, Jaiswal A, Mehta RT.
    J Asthma; 2024 Oct; 61(10):1181-1189. PubMed ID: 38488853
    [Abstract] [Full Text] [Related]

  • 28. Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids.
    Lötvall J, Bateman ED, Busse WW, O'Byrne PM, Woodcock A, Toler WT, Jacques L, Goldfrad C, Bleecker ER.
    J Negat Results Biomed; 2014 Jun 13; 13(1):9. PubMed ID: 24928338
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily.
    Kerwin EM, Nathan RA, Meltzer EO, Ortega HG, Yancey SW, Schoaf L, Dorinsky PM.
    Respir Med; 2008 Apr 13; 102(4):495-504. PubMed ID: 18206361
    [Abstract] [Full Text] [Related]

  • 30. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.
    O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, Jacques L, Lötvall J.
    Eur Respir J; 2014 Mar 13; 43(3):773-82. PubMed ID: 24136330
    [Abstract] [Full Text] [Related]

  • 31. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG, Prosser TR.
    Ann Pharmacother; 2014 Feb 13; 48(2):250-7. PubMed ID: 24259654
    [Abstract] [Full Text] [Related]

  • 32. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R.
    Respir Med; 2015 Mar 13; 109(3):329-38. PubMed ID: 25661281
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun 13; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 34. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
    Bateman ED, O'Byrne PM, Busse WW, Lötvall J, Bleecker ER, Andersen L, Jacques L, Frith L, Lim J, Woodcock A.
    Thorax; 2014 Apr 13; 69(4):312-9. PubMed ID: 24253831
    [Abstract] [Full Text] [Related]

  • 35. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A.
    Respir Med; 2015 Jul 13; 109(7):870-81. PubMed ID: 26006754
    [Abstract] [Full Text] [Related]

  • 36. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
    Oliver A, VanBuren S, Allen A, Hamilton M, Tombs L, Inamdar A, Kempsford R.
    Clin Ther; 2014 Jun 01; 36(6):928-939.e1. PubMed ID: 24793536
    [Abstract] [Full Text] [Related]

  • 37. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I, Williams M, Power S, Pilcher J, Weatherall M, Baines A, Moynihan J, Kempsford R, Beasley R, FF/VI Study Team.
    Respir Med; 2016 Oct 01; 119():115-121. PubMed ID: 27692131
    [Abstract] [Full Text] [Related]

  • 38. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C.
    Eur Respir J; 2014 Mar 01; 43(3):763-72. PubMed ID: 24114969
    [Abstract] [Full Text] [Related]

  • 39. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D, Tombs L, Preece A, Brealey N, Mehta R.
    Pulm Pharmacol Ther; 2014 Oct 01; 29(1):49-57. PubMed ID: 25020273
    [Abstract] [Full Text] [Related]

  • 40. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.
    Busse WW, O'Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED.
    Thorax; 2013 Jun 01; 68(6):513-20. PubMed ID: 23440247
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.